Growth Hormone-Releasing Hormone Agonists Reduce Myocardial Infarct Scar in Swine With Subacute Ischemic Cardiomyopathy [Heart Failure]

Conclusions
Daily subcutaneous administration of GHRH-A is feasible and safe in a large animal model of subacute ischemic cardiomyopathy. Furthermore, GHRH-A therapy significantly reduced infarct size and improved diastolic strain, suggesting a local activation of the GHRH pathway leading to the reparative process.

Source: JAHA:Journal of the American Heart Association - March 31, 2015 Category: Cardiology Authors: Bagno, L. L., Kanashiro-Takeuchi, R. M., Suncion, V. Y., Golpanian, S., Karantalis, V., Wolf, A., Wang, B., Premer, C., Balkan, W., Rodriguez, J., Valdes, D., Rosado, M., Block, N. L., Goldstein, P., Morales, A., Cai, R.-Z., Sha, W., Schally, A. V., Hare, Tags: Heart Failure Source Type: research